Zalifrelimab

DB15632InvestigationalProtein Based Therapies

Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4
Curator reviewed
Code names: AGEN-1884

Resolves to

Compound

UNIIFE7L22H028CAS2148321-69-9

Targets

P16410CTLA4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zalifrelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account